Telos Biotech™ is managed by an accomplished team with a shared vision of revolutionizing cell therapies
Co-Founder
Read full bio
.svg)
Enzo Tedone obtained his Ph.D. from the University of Milan with focus on the discovery of new biomarkers of healthy aging. He was a post-doctoral fellow at UT Southwestern Medical Center in the lab of Jerry W. Shay, studying the relationship of telomere shortening and aging and new approaches for safely elongating shortened telomeres. He is a recipient of the 2019 Forbeck Scholar Award, as well as the author of eighteen scientific publications and one US Patent.
Co-Founder
Read full bio
Mohammad E. Sayed is a Co-Founder and pioneering scientist at Telos. He holds a Ph.D. obtained from Dr. Shay's lab at UT Southwestern Medical Center, where he specialized in studying cancer as a disease of aging. Throughout his career, Dr. Sayed has dedicated himself to unraveling the underlying mechanisms driving both cancer and aging, with the ultimate goal of developing targeted therapies. His research has encompassed a diverse range of subjects, including protein engineering, alternative splicing (RNA biology), and adoptive cell and gene therapies, resulting in his extensive expertise in these areas. He is the author of seven scientific publications and one US Patent.
Scientific Founder
Read full bio
Jerry Shay is the Associate Director of the Harold Simmons NCI Designated Comprehensive Cancer Center, a Distinguished Chair in Geriatrics Research, and a consultant and scientific advisory board member for companies such as Procter Gamble, Corixa, BioWhitaker, Clontech, Rexahn, Sierra Science and Elizabeth Therapeutics. He co-founded Geron Corporation focused on telomerase therapeutics and is the Scientific Founder and member of the SAB for Barricade Therapeutics focused on developing a targeted therapy for colon cancer. Jerry is also the Scientific Founder and Chairman of the Scientific Advisory Board of THIO, part of Maia Biotechnology, an early-stage company developing targeted therapies with novel mechanisms of action. He received his BA from UT Austin and PhD from UC Boulder.
Board Director
EVP, Business Development
Cambrian Bio
Read full bio
Mark Nuttall is the Executive Vice President of Business Development at Cambrian Bio. He was previously Chief Business Officer for Kintai Therapeutics/Senda Biosciences, a Flagship Pioneering company, and Kymera Therapeutics (KYMR). Before moving to biotech, Mark held increasingly senior roles in business development functions at several large pharmaceutical companies. He was Vice President and Head of Business Development & Licensing for core therapeutic franchises at Sanofi Genzyme: immunology, inflammation and multiple sclerosis; at Johnson & Johnson, he led neuroscience business development and was responsible for leading a team that transformed J&J’s CNS portfolio. Mark began his career in the healthcare industry in R&D at GlaxoSmithKline and AstraZeneca. He has a B.Sc. in biochemistry from the University College of Wales in Cardiff and a Ph.D. in molecular and cell biology from the University of Aberdeen, Scotland.
Board Chairman
EVP, Drug Discovery
Cambrian Bio
Read full bio
Georg C. Terstappen is the Executive Vice President of Drug Discovery at Cambrian Bio. He has 30 years of experience in big pharma/biotech, holding R&D leadership positions at Bayer, GW/GSK, and Abbott/AbbVie –most recently as Head of Preclinical CNS Drug Development with GSK. Georg was also Co-Founder/CSO of Siena Biotech and CSO of OxStem (a University of Oxford spin-out company). In addition, Georg has led EU R&D framework organizations as Vice-Chair of the Innovative Medicines Strategy group in the context of EFPIA and IMI. He was also adjunct professor/visiting scientist at several universities, including the University of Oxford, and leader of European-wide research programs funded by the EC. Georg has published 90 scientific articles and is inventor/co-inventor of 15 patents. He has a first-class honors degree in Biology and conducted research at the Max-Planck-Institute and the Federal Research Centre Juelich, for which he has received a PhD in natural sciences.
Senior Director
R&D Project Management
Cambrian Bio
Read full bio
Claire O’Brien is a Senior Director of Research & Development Project Management at Cambrian Bio. She has 30 years of experience in developing medicines at Ipsen, GlaxoSmithKline (including Glaxo Wellcome and Glaxo Group Research), and in biotech, an in-depth knowledge of medicine development, and a track record in leading global, matrixed teams to advance programs through discovery, development, and launch. After earning a degree in chemistry at Kingston University London, she spent ten years in formulation and analytical development, then moved into cross-functional project leadership, working in multiple disease areas and with teams across US, EU, China, and Japan. Her deep interest in the development and growth of talent has been a theme throughout her career, and she has been coaching for 15 years with a particular interest in coaching scientists to lead.
Director
Business Development
Cambrian Bio
Read full bio
Erik Schneider is a Director of Business Development at Cambrian Bio. Previously, he was on the Business Development and Licensing team at Novartis, evaluating deal and portfolio strategy across cardiovascular, immunology, and neuroscience franchises. Prior to joining Novartis, Schneider was a consultant at CBPartners (now Trinity Life Sciences), with a focus on commercial and pricing strategy for new products. Schneider graduated from the College of the Holy Cross with a degree in Biochemistry.
.svg)
.svg)
.svg)